Immune mechanisms have a significant role in antitumour response and cancer development ([@bib36]). Testicular germ cell tumours (GCTs) have an exceptional sensitivity to platinum-based chemotherapy ([@bib13], [@bib14]; [@bib28]; [@bib37]; [@bib38]). However, patients who fail front-line and salvage chemotherapy are rendered incurable ([@bib41]; [@bib15]). Scientific uncertainty regarding mechanisms of resistance to chemotherapy leads to further research in an effort to understand treatment failure in this subset of GCT patients ([@bib46]; [@bib51]; [@bib2]). Numerous studies confirmed the efficacy of the check-point inhibition in various types of malignancies in recent years ([@bib54]; [@bib19]; [@bib45]; [@bib3]; [@bib18]). Furthermore, the expression of programmed death receptor 1 ligand (PD-L1) on tumour cells and tumour infiltrating lymphocytes (TILs) has shown a significant prognostic power in our series of patients ([@bib10]; [@bib8]). The inflammatory tumour microenvironment (TME) has many roles in tumour progression and metastasis. Simple blood test such as complete blood count (CBC) can identify immune-inflammatory elements (neutrophils, lymphocytes and platelets) that might shed light on the inflammatory TME ([@bib36]; [@bib33]). Immune inflammatory cells have proven to be prognostic in several types of cancer, including urothelial, colorectal, renal cell cancer and mesothelioma ([@bib27]; [@bib25]; [@bib48]; [@bib22]; [@bib47]). Neutrophil to lymphocyte ratio was previously developed as a prognostic tool and was widely tested in other solid tumours ([@bib58]; [@bib62]; [@bib4]). Additional value of platelets was suggested, as platelets were shown to protect circulating tumour cells from shear stress during circulation, induce epithelial--mesenchymal transition and promote tumour extravasation to metastatic sites ([@bib29]; [@bib44]; [@bib49]). Neutrophils, lymphocytes, and platelets have been recently used in a joined tool, a systemic immune-inflammation index (SII), to provide prognostic information in patients with malignant tumours ([@bib21]; [@bib34]). It was established that SII provides a more powerful tool combining three independent prognostic factors compared to platelets, neutrophil to lymphocytes- or neutrophil to platelets-based tools in cancer ([@bib20]; [@bib57]; [@bib59]). High SII reflects pro-inflammatory activity, which was linked to progression, metastasis and poor outcome in cancer ([@bib50]; [@bib12]). SII was also associated with higher counts of circulating tumour cells ([@bib21]; [@bib61]). In this study, we evaluated the prognostic value of SII in GCTs and correlated with PD-L1 expression on tumour cells and TILs.

Patients and methods
====================

This retrospective translational study included a discovery set (DS) of 171 patients with GCTs treated from 1999 to 2015 in the National Cancer Institute in Slovakia, with available CBC before systemic platinum-based chemotherapy and sufficient follow-up clinical data. A validation set (VS) consisted of 181 patients included in our previous translational trial of 240 patients evaluating a prognostic significance of PD-L1 on TILs in GCTs, for whom baseline CBC data and sufficient follow-up clinical data were available ([@bib8]). In contrast, the current study aimed to evaluate the prognostic significance of SII and explore its' associations with PD-L1 expression in GCTs. Clinical data were recorded and compared with SII and PD-L1 expression on TILs. The Institutional Review Board approved this study and a waiver of consent form for patients was granted.

Systemic immune-inflammation index
----------------------------------

The SII is an index based on platelets (*P*), neutrophils (*N*) and lymphocytes (*L*) counts. It was calculated using the following formula: SII=*P* × *N*/*L* as defined previously ([@bib21]). The median value was used as the cutoff value of SII, which was then dichotomised into low (below median) and high (above median) categories.

Tumour pathology, tissue microarray construction and immunohistochemical staining for PD-L1
-------------------------------------------------------------------------------------------

The present study assessed the association of SII with the PD-L1 expression, which was evaluated in 181 of 240 patients in our previous translational study ([@bib8]). Tumour specimens collected before the administration of systemic therapy were reviewed by two pathologists associated with the study and PD-L1 expression was evaluated in tumour and on TILs as described previously ([@bib8]). Germ-cell tumours were identified according to the World Health Organisation criteria ([@bib40]). Tissue microarray construction and immunohistochemical staining with rabbit anti-PD-L1 monoclonal antibody was described in detail previously ([@bib8]). Tumour infiltrating lymphocytes were identified with haematoxylin--eosin staining according to the typical morphology. Tumour cells and TILs with PD-L1 expressions were scored by a weighted histoscore (HS), which accounts for both the extent of cell staining (*S*) and the staining intensity (*I*) ([@bib26]). Positively staining cells were estimated on a scale from 0 to 100%. Subsequently, a score from 0 to 3 (0=no staining; 1=weak; 2=intermediate; and 3=strong staining) was assigned to describe the average intensity of positively staining cells. The HS was then calculated by following formula: *S* × *I*; to yield a scale from 0 to 300. On the basis of the HS, a PD-L1 expression was graded as low (0--150) or high (160--300) as we described previously ([@bib39]). The highest PD-L1 expression among GCT subtypes was chosen for mixed GCTs.

Statistical analysis
--------------------

A Shapiro--Wilk test have shown a significant difference from the normal distribution of PD-L1 HS, therefore non-parametric tests were used for analyses. Differences in distributions of PD-L1 expression between two groups of patients were analysed using the Mann--Whitney *U* test. For analyses of associations between the SII and PD-L1 expression, a one-way analysis of variance was used when using PD-L1 as a continuous variable. We used Fisher's exact test to assess the associations between SII and PD-L1 when used as categorical variables.

A median follow-up time was identified as a median time duration since the diagnosis to the time of the last follow-up. Progression-free survival (PFS) was calculated from the date of orchiectomy or tumour biopsy to the date of progression or death or the date of the last adequate follow-up. Overall survival (OS) was calculated from the date of diagnosis to the date of death or last follow-up. We performed a Kaplan--Meier analysis to estimate PFS and OS using a product limit method and and we subsequently compared the results by the log-rank test. A multivariable analysis was performed using Cox proportional hazards model for PFS and OS to assess the differences in prognosis on the basis of SII and PD-L1 expression and a prognosis according to International Germ Cell Cancer Collaborative Group (IGCCCG) criteria ([@bib26]). All reported *P*-values were two-sided. A *P*-value \<0.05 was considered as significant. Statistical analyses were performed using NCSS 10 software (NCSS, 2015, LLC. Kaysville, UT, USA, [ncss.com/software/ncss](ncss.com/software/ncss)).

Results
=======

Patients' characteristics from discovery and VSs are shown in [Table 1](#tbl1){ref-type="table"}. Majority of patients in the discovery and the VS had a non-seminoma histology. A testicular tumour was the most common primary site and more than half of patients were in a good risk category according to the IGCCCG criteria. The median follow-up in the DS was 49 months (0--170) for all patients and 49 months (7--179) for patients still alive. During the follow-up, 42 (25%) patients experienced a disease progression and 34 (20%) patients have died. The estimated 5-year PFS and OS was 75% (95% confidence interval (CI) 68--81%) and 78% (95% CI 73--86%), respectively. The median time of follow-up in the VS was 85 months (0--189) for all patients and 90 months (22--189) for patients still alive. During the follow-up, 42 (25%) of these patients experienced a disease progression and 34 (20%) have died. The estimated 5-year PFS and OS was 89% (95% CI 84--9%) and 91% (95% CI 87--95%), respectively. We attribute the difference in 5-year survival between the DS and the VS to the higher proportion of IGCCCG good-risk patients and lower proportion of IGCCCG poor-risk patients in the VS ([Table 1](#tbl1){ref-type="table"}).

Association between the SII and patient/tumour characteristics
--------------------------------------------------------------

We found strongly significant correlations between the SII and poor patients' characteristics in both cohorts ([Table 2](#tbl2){ref-type="table"}). Poor and intermediate risk IGCCCG categories and multiple metastatic sites were associated with the high SII in both groups (all *P*\<0.001). Bulky retroperitoneal disease, liver or other non-visceral pulmonary metastases (NPVM) were also significantly associated with the high SII (all *P*\<0.001). Moreover, the high SII was also associated with high tumour markers (both *P*\<0.001). The SII did not significantly differ between seminomas and non-seminomas, although it was significantly higher in patients with extragonadal primary in the DS but not in the VS (*P*\<0.001 *vs* 0.238).

A prognostic role of the SII
----------------------------

Median SII in DS was 1003. Patients with low SII (SII\<1003) had a significantly longer PFS (HR=0.22, 95% CI 0.12--0.41, *P*\<0.001) ([Figure 1A](#fig1){ref-type="fig"}) and OS (HR=0.16, 95% CI 0.08--0.32, *P*\<0.001) ([Figure 1B](#fig1){ref-type="fig"}) opposite to patients with high SII (SII ⩾1003).

A model with median obtained from the discovery data set was tested in an independent VS as defined above. This analysis confirmed prognostic value of SII in GCTs. Patients within the VS, who had a low SII, calculated with a median obtained from the DS had a significantly longer PFS (HR=0.30, 95% CI 0.11--0.81, *P*=0.004) and OS (HR=0.15, 95% CI 0.05--0.47, *P*\<0.001) ([Figure 2](#fig2){ref-type="fig"}) as opposed to patients with the high SII.

Survival analysis of both study cohorts have reported significantly longer PFS (HR=0.22, 95% CI 0.13--0.37, *P*\<0.0001) and OS (HR=0.14, 95% CI 0.08--0.25, *P*\<0.0001) for patients with low SII compared to patients with high SII ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). A multivariable Cox regression analysis has shown that SII was prognostic independently of IGCCCG for OS, but not for PFS when we compared IGCCCG poor *vs* good/intermediate-risk patients ([Table 3](#tbl3){ref-type="table"}). When we performed the multivariable Cox regression analysis with three IGCCCG categories, the analysis lost the statistical significance for OS (data not shown).

The association of the SII and PD-L1 expression
-----------------------------------------------

No statistically significant correlation between the SII and PD-L1 expression on tumour or TILs in the VS was observed. The mean HS for PD-L1 on TILs was 107.3 (95% CI 89.0--125.5) in patients with low SII, compared to 89.1 (95% CI 59.0--119.1) in patients with high SII (*P*=0.376). Similarly, the mean HS for PD-L1 on tumour cells in patients with low *vs* high SII was 79.5 (95% CI 66.2--92.8) *vs* 61.2 (95% CI 41.6--80.8) (*P*=0.199).

A Fisher's exact test of the SII and PD-L1 expression on tumour or TILs also reported no significant correlations (*P*=0.510 and *P*=0.484, respectively).

A combined prognostic role of the SII and PD-L1 expressing TILs
---------------------------------------------------------------

Previously, we have shown the prognostic value of PD-L1 expressing TILs in GCTs (16). In the subsequent analysis, we assessed a combined prognostic value of SII and PDL-1 on TILs within the VS. The analysis identified three prognostic groups of patients. The best prognosis was seen in patients who had a high expression of PD-L1 on TILs (HS ⩾160) and a low SII (SII\<1003) with a 5-year PFS and OS of both 100%, while the worst prognosis was seen in patients with a low expression of PDL1 on TILs (HS \<160) and a high SII (SII⩾1003) with a 5-year PFS and OS of 70% and 70%, respectively (HR=0.29, 95% CI 0.10--0.78; *P*\<0.001 for PFS and HR=0.13, 95% CI 0.04--0.40; *P*\<0.001 for OS) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Patients with SII and PD-L1 on TILs both low or high had similar intermediate prognosis.

Discussion
==========

Immune mechanisms have been associated with the pathogenesis of cancer ([@bib52]). Recent advancements in anticancer treatment with immune therapy unleashing the immunity of the host and driving the anti-tumour response resulted in long-term remissions, and even cure in several malignancies ([@bib6]; [@bib30]; [@bib42]). Testicular cancer has been traditionally referred to as chemotherapy sensitive and few facts are known about the underlying immune mechanisms in this disease. In this study, we analysed a prognostic value of a SII in two independent retrospective cohorts of patients and its association with PD-L1 expression on TILs in our VS. We found that SII calculated prior to chemotherapy is an indicator of prognosis among GCT patients. We did not observe correlation between SII and PD-L1 expression in tumour cells and/or PD-L1 expressing TILs, but the combination of SII and PD-L1 on TILs have created a robust prognostic tool for clinical outcome in GCTs. Our results suggest that immune processes have a role in the mechanisms of progression in GCTs, however, based on our data we cannot determine whether systemic inflammation as expressed by SII creates a permissive microenvironment that leads to the manifestation of the disease with poor prognostic features or if the SII reflects an aggressive disease. However, the ability to predict the clinical outcome using the host's immune parameters could allow the pre-selection of patients with different prognostic profiles and the consequent planning of tailored treatment. Interestingly, [@bib60] recently reported a neutrophil-to-lymphocyte ratio as a simple marker predictive of the presence of stage I testicular cancer. However, [@bib5] evaluated a prognostic significance of pre-orchiectomy neutrophil-to-lymphocyte ratio in GCT patients and observed no difference in PFS and cancer-specific survival. A revised version of the IGCCCG classification (28) has been launched in 2016, which is collecting data also on *P*, *N* and *L* at baseline in patients treated with first-line chemotherapy ([@bib11]). This large series of thousands of cases could contribute to better understanding the impact of these parameters including the SII in GCTs.

A cytokine signalling suggesting pro-inflammatory and immunosuppressive pathways that predicts prognosis in GCTs has been previously described in our works ([@bib9]; [@bib53]). Pro-inflammatory TME has been reported to correspond with poor prognosis in other malignancies as well ([@bib31]; [@bib55], [@bib57]). However, the immune TME and its impact on outcome in patients with GCTs is not entirely clear. The SII in our DS have shown strong correlations with essentially all poor clinical characteristics in GCTs. All correlations with clinical features such as the extra-gonadal primary, bulky retroperitoneal disease, NPVM or elevated tumour markers, were strongly significant. We have demonstrated the prognostic value of SII in GCTs for the first time, evidenced by a significant difference in PFS and OS. These findings were replicated in the independent VS. While all the poor clinical characteristics were significantly associated high SII, similar to the data from the DS, one exception was seen. Only two patients were categorised as having primary extra-gonadal tumour within the VS, which contributed to the low statistical power in this tumour characteristic. In a study by [@bib35], a higher SII was also associated with poor outcome and poor clinical features, such as Gleason score ⩾8, visceral metastases or ECOG ⩾2, in patients with prostate cancer. Similar data were reported by the same group and others in kidney cancer, oesophageal squamous, hepatocellular, gastric or colorectal carcinoma ([@bib23]; [@bib43]; [@bib56]; [@bib34]; [@bib17]). With the recent development of immune therapies, PD-1, PD-L1 and CTLA4 have become treatment targets in cancer. Germ-cell tumours express PD-L1 in abundance, as was shown by Fankhauser and our group previously ([@bib16]; [@bib10]). In addition, PD-L1 but not PD-1 expression was prognostic when expressed on tumour cells and TILs ([@bib10]; [@bib8]). A phase II clinical study from Indiana University evaluating an anti-PD-1 agent pembrolizumab failed to prove an efficacy in the treatment of refractory GCTs ([@bib1]). Initial results in seven cases with platinum-refractory GCTs treated with anti-PD1 agents (pembrolizumab or nivolumab) after high-dose chemotherapy have been recently reported with possible activity in three patients ([@bib64], [@bib63]) and a single case report provided evidence of ongoing partial remission with marker stabilisation with nivolumab ([@bib7]). However, predictive markers associated with tumour response have not been reported and larger prospective clinical trials are suggested. The associations of inflammatory pathways in relation with PD-1/PD-L1 signalling is unknown. Our further investigation of the association of SII and PD-L1 on tumour cells and TILs did not confirm significant correlations among these, suggesting that PD-L1 and SII mirror different aspects of immunity. An analysis of a combined prognostic value of the SII and PD-L1 on TILs in our VS have discovered three groups of patients; (i) with an excellent prognosis (no events reported) if PD-L1 on TILs was high and SII was low, (ii) a poor prognosis if PD-L1 on TILs was low and SII was high, (iii) and an intermediate prognosis if both were low or high. While the survival curves showed smaller differences in patients with better outcomes for OS compared to PFS in this survival analysis, no events were observed in the best prognostic group (100% PFS and 100% OS at 14 years ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). This is an interesting observation, as well established IGCCCG prognostic criteria show 90% 5-year PFS and 97% 5-year OS for good risk patients (1997). Therefore, combined SII and PD-L1 seems to provide more prognostic power compared to the IGCCCG and may be a useful tool for prognosis prediction in the future. We speculate that the favourable prognosis that might be driven by PD-L1 on TILs can be reduced in the pro-inflammatory environment and vice-versa. The underlying mechanism is however unclear and more research is needed to provide a detailed explanation.

Our study have some strengths and limitations. The strength of the study is the existence of DS and VS as well as the size of the patient population. Limitations include the retrospective nature of the analysis and under-representation of extragonadal GCTs. Also, we noted some imbalances between the sets that could be responsible for differences in the median of SII. While the most of patients in both cohorts were in IGCCCG good risk, the VS included less poor risk and extragonadal GCTs than the DS, which could explain lower overall SII index in the VS compared to the DS.

In conclusion, this is the first translational study to show a prognostic potency of SII in GCTs. On the basis of the acquired data, we suggest SII and its' combined prognostic value with PD-L1 as an interesting novel finding that requires further larger and prospective study for validation and implementation into clinical practice. Additional research is needed to provide detailed insights into immunobiology of GCTs and uncover possible implications for treatment of this disease.
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![**Kaplan--Meier estimates of probabilities of PFS and OS according to the SII**. (**A**) Estimates of probabilities of PFS in the discovery set of patients with GCTs (*n*=171), HR=0.22, 95% CI 0.12--0.41, *P*\<0.001; low SII\<1003; high SII⩾1003. (**B**) Estimates of probabilities of OS according to the SII; in the discovery set of patients with GCTs (*n*=171), HR=0.16, 95% CI 0.08--0.32, *P*\<0.001; low SII\<1003; high SII⩾1003. CI=confidence interval; GCTs=germ-cell tumours; HR=hazard ratio; OS=overall survival; PFS=progression--free survival; SII=Systemic immune-inflammation index.](bjc2017460f1){#fig1}

![**Kaplan--Meier estimates of probabilities of PFS and OS according to the SII**. (**A**) Estimates of probabilities of PFS according to the SII; in the validation set of patients with GCTs (*n*=171), HR=0.30, 95% CI 0.11--0.81, *P*=0.004; low SII \<1003. (**B**) Estimates of probabilities of OS according to the SII; in the validation set of patients with GCTs (*n*=171), HR=0.15, 95% CI 0.05--0.47, *P*\<0.001; low SII\<1003; high SII ⩾1003. CI=confidence interval; GCTs=germ-cell tumours; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; SII=Systemic immune-inflammation index.](bjc2017460f2){#fig2}

###### Patient characteristics

                                             **Discovery set**        **Validation set**                  
  ------------------------------------------ ------------------------ --------------------- ------------- ----
  **Age (years)**                                                                                         
   Median (range)                            30 (17--62)                                    30 (16--67)    
  **Histology**                                                                                           
   Pure seminoma                             31                       18                    33            18
   Non-seminoma or mixed GCT                 127                      74                    148           82
   N/A                                       13                       8.0                                  
  **Primary tumour**                                                                                      
   Gonadal                                   143                      84                    179           99
   Extragonadal                              28                       16                    2             1
  **IGCCCG risk group**                                                                                   
   Good risk                                 90                       53                    146           81
   Intermediate risk                         24                       14                    19            11
   Poor risk                                 57                       33                    16            8
  **Sites of metastases**                                                                                 
   Retroperitoneum                           146                      85                    121           67
   Mediastinum                               45                       26                    18            10
   Lungs                                     84                       49                    39            22
   Liver                                     62                       35                    9             5
   Other                                     29                       17                    16            9
   Non-pulmonary visceral metastases         46                       27                    8             4
  **No. of metastatic sites**                                                                             
   0                                         8                        5                     55            30
   1--2                                      103                      60                    101           57
   \>3                                       60                       35                    25            13
  **Mean (range) of pretreatment markers**                                                                
   AFP mIU ml^−1^                            4324 (0--164 946)        998 (0--60 570)                      
   HCG IU ml^−1^                             164 474 (0--1 888 840)   10 633 (0--423 338)                  
   LDH (mkat l^−1^)                          16 (2--130)              12 (1.97--81)                        

Abbreviations: AFP=alpha-fetoprotein; GCT=germ-cell tumour; HCG=human chorionic gonadotropin; IGCCCG=International Germ Cell Cancer Collaborative Group; LDH=lactate dehydrogenase; N/A=not available.

###### Patient characteristics in association with the SII

                                             **Discovery set**   **Validation set**                                             
  ----------------------------------- ----- ------------------- -------------------- ------ --------- ----- ------ ----- ------ ---------
  All patients                         171         1664                 144           1003     NA      181   1034   98    611      NA
  Histology                                                                                                                          
   Seminoma                            31          1259                 336           932     0.703    33    966    231   608     0.059
   Non-seminoma                        127         1686                 166           971              148   1050   109   1437       
   N/A                                 13                                                                                            
  Tumour primary                                                                                                                     
   Primary testicular                  143         1487                 153           909    \<0.001   179   1032   99    600     0.238
   Extragonadal                        28          2571                 347           1627              2    1302   939   1302       
  IGCCCG risk group                                                                                                                  
   Good                                90           900                 178           644    \<0.001   146   744    93    534    \<0.001
   Intermediate                        24          2163                 345           1319             19    1440   258   739        
   Poor                                57          2661                 224           1991             16    3203   281   2961       
  Number of metastatic sites                                                                                                         
   0                                    8           530                 647           467    \<0.001   55    548    153   461    \<0.001
   1--2                                103         1437                 180           751              101   882    113   611        
   ⩾3                                  60          2207                 236           1610             25    2725   227   1785       
  Retroperitoneal LN metastases                                                                                                      
   Absent                              25          1213                 348           709    \<0.001   60    718    159   467    \<0.001
   1--5 cm                             53           760                 239           585              63    767    155   496        
   \>5 cm                              93          2302                 181           2256             55    1605   166   1019       
   N/A                                  0                                                               3                            
  Mediastinal LN metastases                                                                                                          
   Absent                              126         1480                 165           759    \<0.001   163   861    95    569    \<0.001
   Present                             45          2180                 276           1571             18    2609   287   1461       
  Lung metastases                                                                                                                    
   Absent                              109         1447                 178           753    \<0.001   142   760    102   522    \<0.001
   Present                             62          2046                 236           1464             39    2035   195   1153       
  Liver                                                                                                                              
   Absent                              137         1412                 154           794    \<0.001   172   933    95    580    \<0.001
   Present                             34          2683                 310           2411              9    2980   417   3154       
  Non-pulmonary visceral metastases                                                                                                  
   Absent                              125         1357                 162           757    \<0.001   173   950    96    583    \<0.001
   Present                             46          2500                 266           1921              8    2860   448   2952       
  S-stage                                                                                                                            
   0                                   25           799                 339           638    \<0.001   82    614    126   495    \<0.001
   1                                   65           939                 210           660              65    982    141   634        
   2                                   24          2163                 346           1320             21    1416   248   743        
   3                                   57          2662                 225           1991             13    3338   315   2768       

Abbreviations: IGCCCG=International Germ Cell Cancer Collaborative Group; LN=lymph node; NA=not applicable; SII=systemic immune-inflammation index.

###### A multivariable Cox proportional hazards model for PFS and OS assessing differences in outcome on the basis of SII and prognosis according to IGCCCG (*N* = 352)

                                            **PFS**       **OS**                         
  ----------------------------------- ------------------- ---------- ------------------- ----------
  SII in GCTs                               1.6404        0.1337           2.6502        0.0200
   High *vs* low                       (0.8590--3.1324)               (1.1656--6.0256)    
  IGCCCG risk group                         7.5204        \<0.0001         6.8666        \<0.0001
   Poor *vs* intermediate/good risk    (4.0501--13.9645)              (3.3483--14.0819)   

Abbreviations: CI=confidence interval; GCT=germ-cell tumour; HR=hazard ratio; IGCCCG=International Germ Cell Cancer Collaborative Group; OS=overall survival; PFS=progression-free survival; SII=systemic immune-inflammation index.
